Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | NMT1 | P30419 | 8/20 | 0.51 |
| ▸ | NMT2 | O60551 | 7/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 3/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23685586 | 0.99 | SIRT6 (0.53) | SIRT6SIRT1NMT1NMT2CA1 | |
| SCHEMBL14004705 | 0.93 | SIRT6 (0.51) | SIRT6SIRT1NMT1NMT2CA1 | |
| SCHEMBL13997595 | 0.91 | SIRT6 (0.46) | SIRT6SIRT1NMT1NMT2CA1 | |
| SCHEMBL14004856 | 0.90 | SIRT6 (0.52) | SIRT6SIRT1NMT1NMT2CA1 | |
| SCHEMBL14004869 | 0.88 | SIRT6 (0.43) | SIRT6SIRT1NMT1NMT2CA1 | |
| SCHEMBL14002552 | 0.86 | KISS1R (0.40) | SIRT6SIRT1NMT1NMT2TLR2 | |
| SCHEMBL2560446 | 0.85 | SIRT6 (0.70) | SIRT6SIRT1NMT1NMT2CA1 | |
| SCHEMBL21944205 | 0.84 | SIRT6 (0.47) | SIRT6SIRT1NMT1NMT2CA1 | |
| SCHEMBL14002539 | 0.84 | KISS1R (0.38) | SIRT6SIRT1NMT1NMT2TLR2 | |
| SCHEMBL14004899 | 0.84 | SIRT6 (0.49) | SIRT6SIRT1NMT1NMT2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170119907-A1 | Targeted Therapeutics | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119907-A1 | Targeted Therapeutics | ANXA3, ANXA5, ANXA6 | SIRT6 2958/4885SIRT1 4333/4885NMT1 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.